Treatment with dupilumab led to significant improvements in disease remission in patients with bullous pemphigoid, an autoimmune blistering skin disease. The phase 2/3 LIBERTY-BP ADEPT trial ...

Before the FDA approved AstraZeneca’s Fasenra, Nucala was the only therapy for treating eosinophilic granulomatosis with ...

Allied Market Research published a report, titled, "Autoimmune Disease Testing Market by Product Type (Instruments and Consumables and ...

Comorbidities and intercurrent illnesses in people with diabetes may necessitate the use of steroids. Steroids cause or ...

Local pathologies, including folliculitis, dermatitis, bullous impetigo, and systemic pathologies, including cutaneous lupus erythematosus, vasculopathies, and general endocrine disorders, can ...

This week, the FDA approved J&J’s JNJ Tremfya for treating an inflammatory bowel disease condition (“IBD”), ulcerative ...

Sanofi and Regeneron have celebrated a pair of positive clinical trials in inflammatory skin disorders with blockbuster ...

Sanofi SNY and Regeneron REGN announced encouraging data from the confirmatory phase III LIBERTY-CUPID C study evaluating ...

Sanofi and Regeneron’s superstar anti-inflammatory biologic Dupixent is on a roll. | It was a busy day for Sanofi and ...

Regeneron and Sanofi's Dupixent achieves positive Phase 3 results for chronic spontaneous urticaria, meeting key endpoints.

Terence Flynn, an analyst from Morgan Stanley, maintained the Buy rating on Regeneron (REGN – Research Report). The associated price ...